The European Commission has approved the use of the CF therapy Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
Dec. 21, 2012
|
2 min read
July 27, 2012
|
1 min read
The European Medicines Agency (EMA) announced today that it has recommended the approval of the CF drug Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
May 25, 2012
|
2 min read
The Cystic Fibrosis Foundation today applauds the Food and Drug Administration's approval of Kalydeco™ (ivacaftor; previously known as VX-770), a major advance in the search for a cure for cystic fibrosis.
Jan. 31, 2012
|
3 min read